Login to Your Account



Abiraterone Strong in Phase III, but No Worries for Provenge Yet

By Catherine Hollingsworth


Monday, September 13, 2010
Interim data from one of Johnson & Johnson's Phase III trials of abiraterone and prednisone for prostate cancer were shaping up so nicely that an independent data monitoring committee called for stopping the trial early and placing the placebo group on the active drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription